Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, has been named to FORTUNE® magazine's 2022 list of the World's Most Admired Companies, marking its fourth appearance on the list. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, asks top executives, directors and financial analysts to identify the companies with the strongest reputations across various industries. “Labcorp's global network of more than

Labcorp Named to Fortune® Magazine's 2022 ‘World's Most Admired Companies' List for the Fourth Time

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Laboratory Corporation of America Holdings (“Labcorp” or “the Company”) (NYSE: LH). Investors who purchased Labcorp securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/lh. The investigation concerns whether Labcorp and certain of its officers and/or directors have viola

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Laboratory Corporation of America Holdings (LH) Investigation

LOS ANGELES--(BUSINESS WIRE)---- $LH #LH--The Schall Law Firm Encourages Investors in Laboratory Corporation of America Holdings with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Laboratory Corporation of America Holdings with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Laboratory Corporation of America Holdings with Losses of $100,000 to Contact the Firm

BURLINGTON, N.C.--(BUSINESS WIRE)--For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. Labcorp (NYSE: LH), a leading global life sciences company, is making this possible by offering the Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens Healthineers, the physician-ordered blood test helps assess the risk of disease progr

Labcorp to Offer Risk-Scoring Test for People With Advanced Liver Fibrosis Due to NASH

Quest Diagnostics

TARRYTOWN, N.Y.--(BUSINESS WIRE)--The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF Test is exclusively available through collaborations with Labcorp (NYSE: LH) and Quest Diagnostics (NYSE: DGX), providing access (with a physician's order) across the country. This is the first time the test is commercially available in the U.S., following De Novo ma

Siemens Healthineers Launches Enhanced Liver Fibrosis (ELF) Test in the U.S.

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

LabCorp (LH) closed at $271.57 in the latest trading session, marking a +0.26% move from the prior day.

LabCorp (LH) Gains As Market Dips: What You Should Know

Albertsons Companies

FedEx

Phillips 66

Here are five value stocks, ACI, LH, PSX, FDX and SWRAY, matching our criteria.

5 Lucrative PEG Stocks for Value Investors

In the latest trading session, LabCorp (LH) closed at $276.08, marking a -0.62% move from the previous day.

LabCorp (LH) Stock Sinks As Market Gains: What You Should Know

CLEVELAND, Jan. 12, 2022 /PRNewswire/ -- GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors. OmniSeq INSIGHT combines genomic and immune profiling to comprehensively characterize a patient's tumor to identify potential treatment and clinical trial options.

GenomOncology Pathology Workbench to Support OmniSeq INSIGHT℠, a Genomic and Immune Profiling Test That Identifies Potential Treatment and Clinical Trial Options for Solid Tumors

LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why LabCorp (LH) is Poised to Beat Earnings Estimates Again

NEW YORK--(BUSINESS WIRE)-- #Corporation--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Laboratory Corporation of America Holdings (“Labcorp” or the “Company”) (NYSE: LH) on behalf of Labcorp stockholders. Our investigation concerns whether Labcorp has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On January 1, 2022, an article from the New York

LABORATORY CORPORATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Laboratory Corporation of America Holdings on Behalf of Laboratory Corporation Stockholders and Encourages Investors to Contact the Firm

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference

Labcorp to Announce Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022

ArcBest

Bath and Body Works

Cowen

COWN, LH, BBWI, and ARCB qualified as the momentum picks for the day, using the Driehaus strategy.

4 Momentum Picks Screened on Driehaus Strategy

SAN DIEGO--(BUSINESS WIRE)---- $LH #invest--Laboratory Corporation of America Holdings' (LH) Prenatal Tests May be Inaccurate

SHAREHOLDER ALERT: Robbins LLP Investigates Laboratory Corporation of America Holdings (LH) on Behalf of Shareholders

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Laboratory Corporation of America Holdings (“Labcorp” or the “Company”) (NYSE: LH) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Labcorp investments or would like to inquire about potentially pursuing claims to recover your loss under the f

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Laboratory Corporation of America Holdings (LH) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $LH #investors--The Law Offices of Frank R. Cruz Announces Investigation of Laboratory Corporation of America Holdings (LH) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Laboratory Corporation of America Holdings (LH) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Laboratory Corporation of America Holdings (“Labcorp” or the “Company”) (NYSE: LH) investors concerning the Company's possible violations of the federal securities laws. On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect about 85 percent of the time, and that patients who rece

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Laboratory Corporation of America Holdings (LH) on Behalf of Investors

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m. (ET). A live webcast of the fireside chat will be available via the Company website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sciences company that provides vital

Labcorp to Speak Virtually at the 40th Annual J.P. Morgan Healthcare Conference

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LabCorp (LH) Soars to 52-Week High, Time to Cash Out?

LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.

LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout

LH vs. WST: Which Stock Is the Better Value Option?

LH vs. WST: Which Stock Should Value Investors Buy Now?

Academy Sports and Outdoors

Avis Budget Group

Penske Automotive Group

West Fraser Timber Co. Ltd.

Given the prevailing sentiment in the market, Academy Sports (ASO), Avis Budget (CAR), Laboratory Corporation (LH), Penske Automotive (PAG) and West Fraser (WFG) are expected to give handsome returns to momentum investors.

5 Momentum Stocks Bargain Hunters Would Love Chasing

Laboratory Corp of America Holdings (NYSE: LH) has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products. Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.

News for Labcorp Holdings Inc Stock (LH)